MedTrace Logo

PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection

NCT01395030 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2018-09-26

Study results available
· View outcomes & findings →

Summary

This clinical trial studies positron emission tomography (PET)/computed tomography (CT) in diagnosing patients with liver cancer undergoing surgical resection. Diagnostic procedures, such as fluorine-18 fluoromethylcholine PET/CT, may help find and diagnose liver cancer.

Conditions

  • Adult Hepatocellular Carcinoma
  • Localized Resectable Adult Liver Carcinoma

Interventions

DIAGNOSTIC_TEST

Computed Tomography

Undergo FCH PET/CT

DRUG

18F-fluoromethylcholine

Undergo FCH PET/CT

DIAGNOSTIC_TEST

Positron Emission Tomography

Undergo FCH PET/CT

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Queen's Medical Center

    lead OTHER

Principal Investigators

  • Sandi Kwee, MD · Queen's Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-15
Primary Completion
2017-05-31
Completion
2018-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01395030 on ClinicalTrials.gov